Pathogen-Directed Antimicrobial Guide

1. An MIC Is Not a Score

The commonest error in reading a culture report is comparing Minimum Inhibitory Concentration values between drugs of different classes. They are not on the same scale, and an MIC means something only against the breakpoint for that one drug.

An Escherichia coli isolate comes back ciprofloxacin sensitive at an MIC of 0.25 mcg/mL and cefoperazone-sulbactam sensitive at 16 mcg/mL. Ciprofloxacin is not therefore the more potent option. A standard intravenous dose of ciprofloxacin reaches a peak serum concentration of about 3 to 4 mcg/mL, so an MIC of 0.25 leaves a narrow margin. Cefoperazone at a standard dose reaches above 150 mcg/mL, against which an MIC of 16 is left far behind.

2. The Same Isolate Can Be Susceptible and Resistant at Once

CLSI publishes two sets of pneumococcal penicillin breakpoints: meningeal susceptible at an MIC of 0.06 mcg/mL or less, non-meningeal susceptible at 2 mcg/mL or less. An isolate at 0.5 is therefore resistant if it came from cerebrospinal fluid and susceptible if it came from sputum. The organism has not changed; the concentration achievable at the site has.

• A laboratory report must say which breakpoint set was applied.
• A national susceptibility figure quoted without that qualifier can be actively misleading. ICMR AMRSN 2024 reports 100 per cent pneumococcal penicillin susceptibility by non-meningeal breakpoints, and among 8 cerebrospinal fluid isolates only 2 of 8 were susceptible by meningeal ones.

3. Choosing Between Agents That Are All Reported Sensitive

1. Compartment penetration. Can the molecule reach the infected space? Echinocandins do not reach the eye, the central nervous system or the urine. Daptomycin is inactivated by pulmonary surfactant. Macrolides do not cross the blood-brain barrier.
2. Bactericidal requirement. Endocarditis, meningitis and profound neutropenia need a bactericidal agent.
3. Collateral disruption. Ceftriaxone and clindamycin both carry a substantial association with Clostridioides difficile colitis.
4. Host toxicity. A beta-lactam is preferred over an aminoglycoside or a polymyxin wherever renal function is borderline.

4. Intrinsic Resistance Is Not on the Report

A susceptibility panel tests what was requested. It does not warn that Proteus, Morganella, Providencia and Serratia are intrinsically resistant to the polymyxins and to tigecycline, that Listeria is intrinsically resistant to every cephalosporin, or that Mucorales are intrinsically resistant to voriconazole. This tool prints the intrinsic profile alongside every result for that reason.

5. Indian Resistance Surveillance

From the ICMR Antimicrobial Resistance Research and Surveillance Network Annual Report 2024, the eighth edition, covering 99,027 culture-positive isolates from tertiary care hospitals during 2024. The report's own caveat is worth reproducing: because the network collects data from tertiary care hospitals, it is not reflective of community levels of resistance and should not be extrapolated to community settings.

Three readings matter more than the individual numbers.

• Methicillin resistance in Staphylococcus aureus has risen steadily across eight years of surveillance. That makes empiric anti-MRSA cover defensible for severe staphylococcal sepsis, and makes de-escalation to a beta-lactam on an MSSA report the step where the mortality benefit sits.
• Carbapenem susceptibility in Klebsiella is close to a coin toss in a tertiary intensive care unit. That does not make a carbapenem the wrong empiric choice, but it does make the 48-hour review compulsory.
• Vancomycin resistance differs tenfold between the two clinical enterococci, so species identification changes the answer.